NEXIMMUNE, INC.

Analyst Reco. NexImmune, Inc.

Equities

NEXI

US65344D2080

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-17 pm EDT			5-day change	1st Jan Change
3.336 ^USD	-3.02%		-7.33%	+50.27%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 16	NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Raymond James Downgrades NexImmune to Market Perform From Outperform	22-11-15	MT
Raymond James Adjusts NexImmune's Price Target to $3 from $12, Maintains Outperform Rating	22-08-16	MT
Barclays Cuts Price Target on NexImmune to $2 From $7, Keeps Overweight Rating	22-08-16	MT
Cantor Fitzgerald Adjusts Price Target for NexImmune to $4 From $35, Maintains Overweight	22-06-30	MT
BTIG Starts NexImmune at Buy With $5 Price Target	22-06-01	MT
Barclays Raises NexImmune's Price Target to $7 From $4, Maintains Overweight Rating	22-04-01	MT
Raymond James Adjusts NexImmune's Price Target to $13 from $21, Maintains Outperform Rating	22-02-22	MT
Raymond James Adjusts Price Target on NexImmune to $21 From $30, Keeps Outperform Rating	21-11-15	MT
NEXIMMUNE : Raymond James Initiates Coverage on NexImmune With Outperform Rating, $30 Price Target	21-04-01	MT
NEXIMMUNE : Cantor Fitzgerald Starts NexImmune at Overweight With $35 Price Target	21-03-09	MT
NEXIMMUNE : Barclays Starts NexImmune at Overweight With $35 Price Target	21-03-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW